OneDigital Investment Advisors LLC Raises Stock Position in argenx SE (NASDAQ:ARGX)

OneDigital Investment Advisors LLC raised its stake in shares of argenx SE (NASDAQ:ARGX) by 13.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,194 shares of the company’s stock after acquiring an additional 139 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in argenx were worth $647,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Blue Trust Inc. increased its position in shares of argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares in the last quarter. J.Safra Asset Management Corp boosted its stake in argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after purchasing an additional 59 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of argenx in the second quarter valued at about $76,000. Finally, Cromwell Holdings LLC raised its position in shares of argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analysts Set New Price Targets

ARGX has been the subject of several research reports. William Blair raised shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Barclays upgraded argenx from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, August 6th. Wedbush boosted their price objective on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research note on Friday, July 26th. Oppenheimer raised their target price on argenx from $560.00 to $646.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, Guggenheim lifted their price target on argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and an average target price of $619.79.

argenx Price Performance

ARGX opened at $574.54 on Wednesday. The business has a fifty day moving average price of $553.99 and a 200 day moving average price of $485.19. argenx SE has a 12 month low of $327.73 and a 12 month high of $611.22. The stock has a market capitalization of $34.36 billion, a price-to-earnings ratio of -652.89 and a beta of 0.61.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same period in the prior year, the firm earned ($1.25) earnings per share. On average, research analysts anticipate that argenx SE will post 2.2 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.